Get the Stockscreener App
158.72
0.61%
-0.92
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $158.72, with a volume of 994.67K.
It is down -0.61% in the last 24 hours and down -0.05% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$159.64
Open:
$161.43
24h Volume:
994.67K
Relative Volume:
0.32
Market Cap:
$246.07B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
47.67
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-2.48%
1M Performance:
-0.05%
6M Performance:
-17.92%
1Y Performance:
+95.65%
1-Day Range:
$158.13
$161.51
1-Week Range:
$156.74
$163.96
52-Week Range:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
158.66 | 247.59B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,122.05 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.50 | 641.88B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.94 | 450.61B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.50 | 357.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca stock gains as analysts see upside ahead of next earnings - ad-hoc-news.de
AstraZeneca stock heads into the open after a modest London gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 0.93% gain - ad-hoc-news.de
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? - Yahoo Finance
AstraZeneca’s New Cholesterol Combo Trial Could Reshape Its Heart-Health Portfolio - TipRanks
Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained - marketscreener.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche - Proactive financial news
AstraZeneca stock edges higher as Deutsche Bank sticks to Sell after COPD data - ad-hoc-news.de
AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success - ad-hoc-news.de
AstraZeneca PLC : Gets a Sell rating from Deutsche Bank - marketscreener.com
Can AstraZeneca (LSE:AZN) Stock Extend Its Rally On A Fresh Wave Of Oncology Approvals? - Kalkine Media
AstraZeneca stock heads into the open after a modest September 9, 2026 gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 2.0 percent drop - ad-hoc-news.de
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough - GuruFocus
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca stock gains analyst support as RBC sets 14,500p target - ad-hoc-news.de
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive financial news
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - ad-hoc-news.de
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - uk.finance.yahoo.com
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
AstraZeneca falls Tuesday, underperforms market - MarketWatch
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca sees positive results from lung cancer drug trial - Sharecast.com
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):